Biopharma investors zero in on oncology and immunology

Biopharma investors are staying focused on the oncology and immunology sectors as major mergers fuel growth in those areas, according to an April 30 report from The Compass.

Advertisement

Changes in disease burden can influence mergers and acquisitions (M&A) activity in these sectors. The report found an increase in new patients associated with oncology providers in recent years. 

In March, Pfizer announced its intention to acquire cancer therapeutics company Seagen for $43 billion. The acquisition amount exceeds the prices of all of Pfizer’s acquisitions since 2019, according to the report.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Innovation

Advertisement

Comments are closed.